Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (7): 3178-3186.doi: 10.4103/NRR.NRR-D-24-01273

Previous Articles     Next Articles

Bone marrow mesenchymal stem cells protect against cerebral amyloid angiopathy by enhancing neutrophil mitocytosis 

Mengyan Hu1, 2, #, Haotong Yi1, #, Shisi Wang1, Xinmei Kang1, Yuxin Liu1, Zhiruo Liu1, Huipeng Huang1, Qin Qin1, Liling Yuan1, Wei Cai1, Wei Qiu1, Zhengqi Lu1, *, Sanxin Liu1, *   

  1. 1Department of Neurology, Mental and Neurological Disease Research Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China;
    2Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangzhou, Guangdong Province, China
  • Online:2026-07-15 Published:2026-03-31
  • Contact: Sanxin Liu, MD, liusx26@mail.sysu.edu.cn; Zhengqi Lu, MD, PhD, luzhq@mail.sysu.edu.cn.
  • Supported by:
    This work was supported by the Guangdong Basic and Applied Basic Research Foundation, No. 2023A1515110543 (to XK); National Natural Science Foundation of China, Nos. 82471335 and 82171307 (to ZL); Noncommunicable Chronic Diseases-National Science and Technology Major Project, No. 2023ZD0504803 (to ZL); Science and Technology Program of Guangzhou, No. 202201020588 (to ZL); China Postdoctoral Science Foundation, No. 2023M744023 (to MH); Guangzhou Municipal School (Hospital) Joint Funding (Dengfeng Hospital) Municipal Key Laboratory Construction Project, No. 202102010009 (to ZL).

PDF

9

Abstract:

Current treatments for cerebral amyloid angiopathy are mainly symptomatic and have limited efficacy, and there is a lack of targeted therapies. Mesenchymal stem cell transplantation improves cognitive and motor function in conditions such as Alzheimer’s disease, acute ischemic stroke, and Parkinson’s disease. In addition, mesenchymal stem cell therapy modulates the immune system, reduces neuroinflammation, and improves resolution of brain lesions by cells of the macrophage lineage. Cerebral amyloid angiopathy and Alzheimer’s disease share similar pathologic changes involving amyloid-beta deposition, which contributes to the progression of both diseases and exacerbates cognitive deficits through impaired vascular integrity and neuroinflammation. Therefore, we hypothesized that mesenchymal stem cell therapy could also ameliorate the pathological changes seen in cerebral amyloid angiopathy by modulating the immune response. In this study, we show that bone marrow mesenchymal stem cells have a protective effect in a mouse model of cerebral amyloid angiopathy (Tg-SwDI/B). Bone marrow mesenchymal stem cell treatment improved cognitive function, reduced neuroinflammation, and maintained blood–brain barrier integrity in Tg-SwDI/B mice. Mechanistically, bone marrow mesenchymal stem cell treatment enhanced the expulsion of damaged mitochondria from neutrophils via migrasomes, in a process known as mitocytosis, thereby preserving mitochondrial quality within the neutrophils. Mitochondrial damage in neutrophils leads to cellular injury, including the generation of reactive oxygen species and the formation of neutrophil extracellular traps. Neutrophils activate mitocytosis to promote mitochondrial renewal, which further enhances their own clearance by macrophage lineage cells. Our findings demonstrate that bone marrow mesenchymal stem cells are a promising therapeutic candidate for cerebral amyloid angiopathy, as they play a significant role in migrasome-dependent mitochondrial quality control in neutrophils.

Key words: bone marrow mesenchymal stem cell, cerebral amyloid angiopathy, cognitive decline, migrasome, mitochondria, neutrophil mitocytosis